Correlation Between Seres Therapeutics and DiaMedica Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Seres Therapeutics and DiaMedica Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Seres Therapeutics and DiaMedica Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Seres Therapeutics and DiaMedica Therapeutics, you can compare the effects of market volatilities on Seres Therapeutics and DiaMedica Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Seres Therapeutics with a short position of DiaMedica Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Seres Therapeutics and DiaMedica Therapeutics.

Diversification Opportunities for Seres Therapeutics and DiaMedica Therapeutics

0.12
  Correlation Coefficient

Average diversification

The 3 months correlation between Seres and DiaMedica is 0.12. Overlapping area represents the amount of risk that can be diversified away by holding Seres Therapeutics and DiaMedica Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on DiaMedica Therapeutics and Seres Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Seres Therapeutics are associated (or correlated) with DiaMedica Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of DiaMedica Therapeutics has no effect on the direction of Seres Therapeutics i.e., Seres Therapeutics and DiaMedica Therapeutics go up and down completely randomly.

Pair Corralation between Seres Therapeutics and DiaMedica Therapeutics

Given the investment horizon of 90 days Seres Therapeutics is expected to under-perform the DiaMedica Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Seres Therapeutics is 1.19 times less risky than DiaMedica Therapeutics. The stock trades about -0.15 of its potential returns per unit of risk. The DiaMedica Therapeutics is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest  606.00  in DiaMedica Therapeutics on November 28, 2024 and sell it today you would lose (8.00) from holding DiaMedica Therapeutics or give up 1.32% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Seres Therapeutics  vs.  DiaMedica Therapeutics

 Performance 
       Timeline  
Seres Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Seres Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
DiaMedica Therapeutics 

Risk-Adjusted Performance

Modest

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in DiaMedica Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, DiaMedica Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.

Seres Therapeutics and DiaMedica Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Seres Therapeutics and DiaMedica Therapeutics

The main advantage of trading using opposite Seres Therapeutics and DiaMedica Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Seres Therapeutics position performs unexpectedly, DiaMedica Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DiaMedica Therapeutics will offset losses from the drop in DiaMedica Therapeutics' long position.
The idea behind Seres Therapeutics and DiaMedica Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Complementary Tools

Fundamental Analysis
View fundamental data based on most recent published financial statements
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance